scholarly journals T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4

2020 ◽  
Vol 295 (33) ◽  
pp. 11486-11494 ◽  
Author(s):  
Charlotte H. Coles ◽  
Catriona McMurran ◽  
Angharad Lloyd ◽  
Miriam Hock ◽  
Linda Hibbert ◽  
...  

T cell-mediated immunity is governed primarily by T cell receptor (TCR) recognition of peptide-human leukocyte antigen (pHLA) complexes and is essential for immunosurveillance and disease control. This interaction is generally stabilized by interactions between the HLA surface and TCR germline-encoded complementarity-determining region (CDR) loops 1 and 2, whereas peptide selectivity is guided by direct interactions with the TCR CDR3 loops. Here, we solved the structure of a newly identified TCR in complex with a clinically relevant peptide derived from the cancer testis antigen melanoma antigen-A4 (MAGE-A4). The TCR bound pHLA in a position shifted toward the peptide's N terminus. This enabled the TCR to achieve peptide selectivity via an indirect mechanism, whereby the TCR sensed the first residue of the peptide through HLA residue Trp-167, which acted as a tunable gateway. Amino acid substitutions at peptide position 1 predicted to alter the HLA Trp-167 side-chain conformation abrogated TCR binding, indicating that this indirect binding mechanism is essential for peptide recognition. These findings extend our understanding of the molecular rules that underpin antigen recognition by TCRs and have important implications for the development of TCR-based therapies.

Immunity ◽  
2012 ◽  
Vol 37 (4) ◽  
pp. 611-621 ◽  
Author(s):  
Sophie E. Broughton ◽  
Jan Petersen ◽  
Alex Theodossis ◽  
Stephen W. Scally ◽  
Khai Lee Loh ◽  
...  

1988 ◽  
Vol 85 (6) ◽  
pp. 14-16 ◽  
Author(s):  
Xiaojiang Gao ◽  
Edward J. Ball ◽  
Lori Dombrausky ◽  
Nancy J. Olsen ◽  
Theodore Pincus ◽  
...  

2016 ◽  
Vol 24 ◽  
pp. S78 ◽  
Author(s):  
Christina Pham ◽  
Aaron Martin ◽  
Jeyaraj Antony ◽  
Daniel MacLeod ◽  
Audrey Brown ◽  
...  

1991 ◽  
Vol 174 (5) ◽  
pp. 1139-1146 ◽  
Author(s):  
B Gulwani-Akolkar ◽  
D N Posnett ◽  
C H Janson ◽  
J Grunewald ◽  
H Wigzell ◽  
...  

We compared T cell receptor (TCR) V-segment frequencies in human leukocyte antigen (HLA) identical siblings to sibling pairs who differ at one or both HLA haplotypes using four V beta-specific and one V alpha-specific monoclonal antibody. In every one of nine families HLA-identical sibs had the most similar patterns of V-segment frequencies in their peripheral blood, whereas totally mismatched sibs were, in general, the most dissimilar; HLA haploidentical sibs tended to be intermediate between the two groups. The degree of similarity among HLA-identical sibs was comparable to that observed among three pairs of identical twins suggesting that HLA is the major genetic component influencing TCR V-segment frequency. Consistent with this observation, it was found that the frequency of T cells expressing particular V beta segments was skewed towards either CD4+ or CD8+ cells indicating that T cells expressing some V beta genes may be positively selected primarily by class I or class II major histocompatibility complex proteins. Finally, it was observed that individuals who express the HLA class I specificity, B38, tend to express high levels of V alpha 2.3+ cells among their CD8+ T cells. These observations represent definitive proof that human V-segment frequencies are profoundly influenced by the HLA complex.


2001 ◽  
Vol 276 (26) ◽  
pp. 24170-24176 ◽  
Author(s):  
Justin W. Chang ◽  
Diane E. Mechling ◽  
Hans-Peter Bächinger ◽  
Gregory G. Burrows

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0154219 ◽  
Author(s):  
Estefanía García-Guerrero ◽  
José Antonio Pérez-Simón ◽  
Luis Ignacio Sánchez-Abarca ◽  
Irene Díaz-Moreno ◽  
Miguel A. De la Rosa ◽  
...  

Immunotherapy ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 89-103 ◽  
Author(s):  
Ian R Hardy ◽  
Wolfgang W Schamel ◽  
Patrick A Baeuerle ◽  
Daniel R Getts ◽  
Robert Hofmeister

Recently, two chimeric antigen receptor (CAR) T cell therapies were approved based on their remarkable efficacy in patients with hematological malignancies. By contrast, CAR-T cell therapies results in solid tumors have been less promising. To develop the next generation of T cell therapies a better understanding of T cell receptor (TCR) biology and its implication for the design of synthetic receptors is critical. Here, we review current and newly developed forms of T cell therapies and how their utilization of different components of the TCR signaling machinery and their requirement for engagement (or not) of human leukocyte antigen impacts their design, efficacy and applicability as cancer drugs. Notably, we highlight the development of human leukocyte antigen-independent T cell platforms that utilize the full TCR complex as having promise to overcome some of the limitations of existing T cell therapies.


Sign in / Sign up

Export Citation Format

Share Document